{"filing":{"accession_number":"0001193125-26-234991","cik":"0000728387","ticker":"CATX","company_name":"Perspective Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"catx-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526234991/catx-20260521.htm"},"events":[{"id":10531,"run_id":9235,"accession_number":"0001193125-26-234991","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The filing discloses interim clinical trial results being presented at a major oncology conference (ASCO 2026). While this could represent material clinical progress for a therapeutics company, the Item 8.01 disclosure lacks sufficient detail to confirm whether these results constitute a formal earnings release, material impairment, or other specific event type. The announcement of interim trial data at a scientific conference is material to investors but does not fit cleanly into the more specific taxonomy categories.","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":6863,"accession_number":"0001193125-26-234991","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses interim clinical trial results being presented at a major oncology conference (ASCO 2026). While this could represent material clinical progress for a therapeutics company, the Item 8.01 disclosure lacks sufficient detail to confirm whether these results constitute a formal earnings release, material impairment, or other specific event type. The announcement of interim trial data at a scientific conference is material to investors but does not fit cleanly into the more specific taxonomy categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:21.855531+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6863,"accession_number":"0001193125-26-234991","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses interim clinical trial results being presented at a major oncology conference (ASCO 2026). While this could represent material clinical progress for a therapeutics company, the Item 8.01 disclosure lacks sufficient detail to confirm whether these results constitute a formal earnings release, material impairment, or other specific event type. The announcement of interim trial data at a scientific conference is material to investors but does not fit cleanly into the more specific taxonomy categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:26:21.855531+00:00","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-05-22"}]}